Drugs / Sinopharm BIBP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05293665 Comparator | Mar → Nov 2022 | — | Vaxxinity, Inc. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinopharm BIBP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293665 ↗ |
| Modality | Vaccine | “Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection” NCT05293665 ↗ |
| Route | Intramuscular | “Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection” NCT05293665 ↗ |